Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-125b-5p AIFM1 -1.42 0 1.21 0 miRNATAP -0.12 1.0E-5 NA
2 hsa-miR-143-5p AIFM1 -1.5 0 1.21 0 miRNATAP -0.13 1.0E-5 NA
3 hsa-miR-145-5p AIFM1 -2.62 0 1.21 0 miRNATAP -0.17 0 20332243 Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death
4 hsa-miR-199a-5p AIFM1 -0.9 0.00031 1.21 0 miRanda -0.11 0.0001 NA
5 hsa-miR-143-3p AKT1 -2.59 0 0.52 0 miRNAWalker2 validate -0.05 0.00136 NA
6 hsa-let-7a-5p AKT2 0.1 0.43289 0.09 0.4188 TargetScan -0.2 0 NA
7 hsa-let-7b-3p AKT2 0.35 0.07056 0.09 0.4188 MirTarget -0.08 0.00243 NA
8 hsa-miR-22-3p AKT2 0.74 0 0.09 0.4188 mirMAP -0.08 0.04433 NA
9 hsa-miR-106a-5p AKT3 2.94 0 -3.43 0 miRNATAP -0.32 0 NA
10 hsa-miR-106b-5p AKT3 2.18 0 -3.43 0 miRNATAP -0.77 0 NA
11 hsa-miR-107 AKT3 1.81 0 -3.43 0 PITA; miRanda -0.75 0 NA
12 hsa-miR-135a-5p AKT3 0.31 0.47441 -3.43 0 miRNATAP -0.09 0.00382 NA
13 hsa-miR-142-3p AKT3 2.07 0 -3.43 0 miRanda -0.18 0.00013 NA
14 hsa-miR-146b-5p AKT3 1.31 0 -3.43 0 miRNAWalker2 validate -0.29 0 NA
15 hsa-miR-15a-5p AKT3 1.78 0 -3.43 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.75 0 NA
16 hsa-miR-15b-5p AKT3 2.5 0 -3.43 0 miRNATAP -0.81 0 NA
17 hsa-miR-16-5p AKT3 1.88 0 -3.43 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.74 0 NA
18 hsa-miR-17-3p AKT3 1.09 0 -3.43 0 miRNATAP -0.46 0 NA
19 hsa-miR-17-5p AKT3 2.27 0 -3.43 0 TargetScan; miRNATAP -0.64 0 NA
20 hsa-miR-181a-5p AKT3 0.97 0 -3.43 0 miRNATAP -0.24 0.00024 NA
21 hsa-miR-181b-5p AKT3 1.3 0 -3.43 0 miRNATAP -0.37 0 NA
22 hsa-miR-181c-5p AKT3 0.6 0.01077 -3.43 0 miRNATAP -0.17 0.00212 NA
23 hsa-miR-20a-5p AKT3 1.51 0 -3.43 0 miRNATAP -0.48 0 NA
24 hsa-miR-20b-5p AKT3 3.36 0 -3.43 0 miRNATAP -0.17 0 NA
25 hsa-miR-29b-2-5p AKT3 0.3 0.11355 -3.43 0 mirMAP -0.14 0.03379 NA
26 hsa-miR-3065-5p AKT3 2.75 0 -3.43 0 mirMAP -0.26 0 NA
27 hsa-miR-32-3p AKT3 2.4 0 -3.43 0 mirMAP -0.54 0 NA
28 hsa-miR-320a AKT3 0.5 0.00226 -3.43 0 PITA; miRanda; miRNATAP -0.37 0 NA
29 hsa-miR-320b AKT3 1.1 0 -3.43 0 PITA; miRanda; miRNATAP -0.38 0 NA
30 hsa-miR-320c AKT3 0.73 0.00058 -3.43 0 PITA; miRanda; miRNATAP -0.29 0 NA
31 hsa-miR-335-3p AKT3 1.32 0 -3.43 0 mirMAP -0.44 0 NA
32 hsa-miR-33a-3p AKT3 1.39 0 -3.43 0 mirMAP -0.46 0 NA
33 hsa-miR-340-5p AKT3 1.35 0 -3.43 0 mirMAP -0.56 0 NA
34 hsa-miR-34c-3p AKT3 0.24 0.65945 -3.43 0 PITA -0.06 0.01923 NA
35 hsa-miR-362-3p AKT3 0.54 0.00242 -3.43 0 miRanda -0.21 0.00314 NA
36 hsa-miR-362-5p AKT3 0.45 0.02925 -3.43 0 PITA; TargetScan; miRNATAP -0.2 0.0011 NA
37 hsa-miR-421 AKT3 2.1 0 -3.43 0 miRanda; mirMAP -0.44 0 NA
38 hsa-miR-501-3p AKT3 2.19 0 -3.43 0 miRNATAP -0.52 0 NA
39 hsa-miR-502-3p AKT3 0.43 0.01008 -3.43 0 miRNATAP -0.2 0.00914 NA
40 hsa-miR-505-3p AKT3 1.38 0 -3.43 0 mirMAP -0.49 0 22051041 We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR
41 hsa-miR-548v AKT3 1.7 0 -3.43 0 miRNATAP -0.21 0 NA
42 hsa-miR-577 AKT3 3.23 0 -3.43 0 mirMAP -0.18 0 NA
43 hsa-miR-616-5p AKT3 1.97 0 -3.43 0 mirMAP -0.34 0 NA
44 hsa-miR-769-5p AKT3 1.41 0 -3.43 0 PITA; miRNATAP -0.67 0 NA
45 hsa-miR-93-5p AKT3 2.58 0 -3.43 0 miRNATAP -0.67 0 NA
46 hsa-miR-335-3p APAF1 1.32 0 -0 0.97011 mirMAP -0.07 0.00422 NA
47 hsa-miR-335-5p APAF1 0.35 0.09622 -0 0.97011 miRNAWalker2 validate -0.13 0 NA
48 hsa-miR-125a-3p ATM 0.77 6.0E-5 -0.95 0 miRanda -0.11 0.00094 NA
49 hsa-miR-146b-5p ATM 1.31 0 -0.95 0 miRanda -0.09 0.00381 27602131 The role of microRNA 146b miR-146b in ATC remains to be elucidated; In order to characterize the role of miR-146b in ATC overexpression or interference of miR-146b was induced in ATC cell lines and cell proliferation and migration were evaluated; The potential targets of miR-146b were searched in the Gene Expression Omnibus database for ATC and matched non-tumor control samples; The expression level of potential targets was detected following overexpression or interference of miR-146b in ATC cell lines; In addition cell migration of ATC was also affected by miR-146b; During the search for potential targets of miR-146b in ATC p21 also known as p21Waf1/Cip1 or CDKN1A was noted for its role in cell cycle progression and tumor pathogenesis; In conclusion p21 may participate in the regulation of ATC cell proliferation by miR-146b
50 hsa-miR-186-5p ATM 1.01 0 -0.95 0 mirMAP -0.13 0.00632 NA
51 hsa-miR-18a-5p ATM 3.22 0 -0.95 0 miRNAWalker2 validate; miRTarBase; MirTarget -0.12 0 23437304; 25963391; 23857602; 23229340 MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases
52 hsa-miR-203a-3p ATM 3.14 0 -0.95 0 MirTarget -0.09 0 24145123; 27542403 miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression
53 hsa-miR-21-5p ATM 1.51 0 -0.95 0 mirMAP -0.1 0.00811 26289851 MiR-21 is an oncomiR that is overexpressed in nearly all cancers including ATC; Hence suppression of miR-21 could pave the way for ATC therapy
54 hsa-miR-324-5p ATM 2.15 0 -0.95 0 miRanda -0.16 0 NA
55 hsa-miR-335-3p ATM 1.32 0 -0.95 0 mirMAP -0.09 0.00248 NA
56 hsa-miR-339-5p ATM 1.79 0 -0.95 0 miRanda -0.16 0 NA
57 hsa-miR-421 ATM 2.1 0 -0.95 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRanda -0.12 1.0E-5 NA
58 hsa-miR-590-3p ATM 1.73 0 -0.95 0 miRanda; mirMAP -0.12 0.00045 NA
59 hsa-miR-590-5p ATM 1.46 0 -0.95 0 mirMAP -0.13 0.00013 NA
60 hsa-miR-766-3p ATM 2.7 0 -0.95 0 MirTarget -0.15 0 NA
61 hsa-miR-92a-3p ATM 1.69 0 -0.95 0 miRNAWalker2 validate -0.12 0.00206 NA
62 hsa-miR-939-5p ATM 2.15 0 -0.95 0 MirTarget -0.12 1.0E-5 NA
63 hsa-miR-30a-5p BAX 0.2 0.42032 0.87 0 miRNAWalker2 validate -0.07 0.00399 NA
64 hsa-miR-103a-3p BCL2 1.51 0 -2.27 0 miRNAWalker2 validate -0.32 3.0E-5 NA
65 hsa-miR-130b-5p BCL2 3.62 0 -2.27 0 mirMAP -0.25 0 27364335 The level of microRNA-130b in relationship with the expression of PPARγ VEGF-A BCL-2 and apoptosis were analyzed in 91 lung cancer patient samples using immunohistochemistry and terminal deoxynucleotidyl transferase dUTP nick end labeling TUNEL assay on tissue microarrays; In vitro and in vivo miR-130b enrichment associated with down-regulation of PPARγ up-regulation of VEGF-A and BCL-2 and decreased apoptosis
66 hsa-miR-142-3p BCL2 2.07 0 -2.27 0 miRanda -0.25 0 NA
67 hsa-miR-15a-5p BCL2 1.78 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.47 0 25594541; 26915294; 18931683; 25623762; 22335947 MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells;The expression of MiR-15a was significantly inhibited by Bcl-2 P < 0.05
68 hsa-miR-15b-3p BCL2 3.25 0 -2.27 0 mirMAP -0.41 0 25594541; 26915294; 26884837; 18449891 MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2
69 hsa-miR-15b-5p BCL2 2.5 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.53 0 25594541; 26915294; 26884837; 18449891 MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2
70 hsa-miR-16-1-3p BCL2 2.09 0 -2.27 0 mirMAP -0.31 0 18931683 MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2
71 hsa-miR-16-2-3p BCL2 2.34 0 -2.27 0 mirMAP -0.43 0 NA
72 hsa-miR-16-5p BCL2 1.88 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.57 0 21336967; 24447552; 18449891; 25435430; 24598659; 18931683; 22966344; 25623762 P glycoprotein enhances radiation induced apoptotic cell death through the regulation of miR 16 and Bcl 2 expressions in hepatocellular carcinoma cells; RHepG2 cells the multidrug resistant subline of human hepatocellular carcinoma HepG2 cells expressed higher levels of Pgp as well as miR-16 and lower level of Bcl-2 than the parental cells; On the other hand ectopic mdr1 expression enhanced radiation-induced apoptosis in HepG2 cells SK-HEP-1 cells MiHa cells and furthermore induced miR-16 and suppressed its target gene Bcl-2 in HepG2 cells; Moreover the enhancement effects of Pgp and miR-16 on radiation-induced apoptosis were counteracted by overexpression of Bcl-2;To study the expression of miR-16 and bcl-2 in T lymphoblastic lymphoma/leukemia T-LBL/ALL and its relationship to prognosis; The relationship of miR-16 and bcl-2 was significantP = 0.042χ2 = 4.147; The relationship of miR-16 and bcl-2 might suggested that gene regulation may be influenced by them;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2;We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells; Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2;The miR-16 expression correlated with BCL-2 protein r = 0.51 P < 0.05;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;The overall objective of our investigation was to assess whether miRNA-16 miR-16 is involved in the regulation of critical genes such as BCL2 that control the sensitivity of pancreatic cancer cells to apoptosis; This study showed that the ectopic overexpression of miR-16 may be therapeutically beneficial as is evidenced by impaired cell survival with concomitant attenuation of anti-apoptotic protein Bcl-2; Moreover the luciferase reporter assay suggested that miR-16 post-transcriptionally regulates Bcl-2 expression in pancreatic cancer cells through the target sites of the 3' untranslated region of this gene;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells
73 hsa-miR-17-5p BCL2 2.27 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.32 0 25435430 Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2
74 hsa-miR-182-5p BCL2 5.18 0 -2.27 0 miRNAWalker2 validate; miRTarBase; mirMAP -0.27 0 23936432; 26870290 Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR 182 and p21; Bcl2 and p21 were identified to be potential target genes of miR-182 in PC3 cells;The expression levels of B-cell lymphoma-2 Bcl-2 and microRNA-182 miR-182 were detected using western blot analysis and quantitative reverse transcription-polymerase chain reaction respectively; Mangiferin treatment was also able to significantly reduce Bcl-2 expression levels and enhance miR-182 expression in PC3 cells; Finally it was observed that mangiferin inhibited proliferation and induced apoptosis in PC3 human prostate cancer cells and this effect was correlated with downregulation of Bcl-2 and upregulation of miR-182
75 hsa-miR-186-5p BCL2 1.01 0 -2.27 0 mirMAP -0.47 0 NA
76 hsa-miR-192-5p BCL2 1.98 0 -2.27 0 miRNAWalker2 validate -0.31 0 26550150 MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192
77 hsa-miR-200a-5p BCL2 4.89 0 -2.27 0 mirMAP -0.26 0 NA
78 hsa-miR-200b-3p BCL2 4.57 0 -2.27 0 miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP -0.23 0 NA
79 hsa-miR-200b-5p BCL2 4.84 0 -2.27 0 mirMAP -0.28 0 NA
80 hsa-miR-200c-3p BCL2 4.2 0 -2.27 0 miRNAWalker2 validate; miRTarBase; mirMAP -0.23 0 NA
81 hsa-miR-20a-3p BCL2 1.64 0 -2.27 0 mirMAP -0.11 0.04522 NA
82 hsa-miR-20a-5p BCL2 1.51 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.17 0.00288 NA
83 hsa-miR-21-5p BCL2 1.51 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.32 1.0E-5 21468550; 25994220; 25381586; 26555418; 23359184; 22964582; 21376256 BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells
84 hsa-miR-215-5p BCL2 2.38 0 -2.27 0 miRNAWalker2 validate -0.33 0 NA
85 hsa-miR-224-5p BCL2 1.55 1.0E-5 -2.27 0 mirMAP -0.1 0.00523 24796455 In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01
86 hsa-miR-24-2-5p BCL2 1.52 0 -2.27 0 miRNAWalker2 validate; miRTarBase -0.41 0 NA
87 hsa-miR-3065-5p BCL2 2.75 0 -2.27 0 mirMAP -0.27 0 NA
88 hsa-miR-32-3p BCL2 2.4 0 -2.27 0 mirMAP -0.32 0 NA
89 hsa-miR-335-3p BCL2 1.32 0 -2.27 0 mirMAP -0.17 0.00274 NA
90 hsa-miR-338-5p BCL2 0.59 0.04471 -2.27 0 PITA -0.17 6.0E-5 NA
91 hsa-miR-33a-5p BCL2 1.05 4.0E-5 -2.27 0 mirMAP -0.14 0.00486 NA
92 hsa-miR-33b-5p BCL2 2.26 0 -2.27 0 miRTarBase; mirMAP -0.23 0 NA
93 hsa-miR-342-3p BCL2 0.91 0 -2.27 0 miRanda -0.19 0.01633 NA
94 hsa-miR-365a-3p BCL2 0.82 1.0E-5 -2.27 0 miRNAWalker2 validate; miRTarBase -0.33 0 NA
95 hsa-miR-375 BCL2 2.57 0 -2.27 0 miRNAWalker2 validate -0.06 0.00889 26381132; 26697569; 25613180 The levels of miR-375 Bax and Bcl-2 protein expression in treated cells were determined by Western blot and RT-PCR; Moreover compared to control group the expression of Bcl-2 and miR-375 decreases with formononetin in the U2OS cells while Bax increases;Exosome Carried microRNA 375 Inhibits Cell Progression and Dissemination via Bcl 2 Blocking in Colon Cancer; RT-PCR for Bcl-2 expression showed that Bcl-2 is down-regulated for miR-375 inhibitor and up-regulated for the miR-375 mimic a result confirmed by Western blotting; The present study brings to the forefront new data that suggest miR-375 as a new player in controlling the pathways responsible for inhibiting the natural history of CRC tumor cells via the Bcl-2 pathway;mRNA levels of ERα Bcl-2 and miR-375 were quantified using real-time polymerase chain reaction; After treatment with biochanin A ERα miR-375 and Bcl-2 expression was significantly upregulated
96 hsa-miR-429 BCL2 5.04 0 -2.27 0 miRNAWalker2 validate; miRTarBase; PITA; mirMAP -0.23 0 23999873; 26513239; 26511969 MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation
97 hsa-miR-577 BCL2 3.23 0 -2.27 0 PITA -0.12 2.0E-5 NA
98 hsa-miR-582-5p BCL2 -0.13 0.57451 -2.27 0 PITA -0.14 0.00591 NA
99 hsa-miR-590-3p BCL2 1.73 0 -2.27 0 miRanda; mirMAP -0.44 0 NA
100 hsa-miR-590-5p BCL2 1.46 0 -2.27 0 miRanda -0.46 0 NA
101 hsa-miR-616-5p BCL2 1.97 0 -2.27 0 mirMAP -0.31 0 NA
102 hsa-miR-629-5p BCL2 1.41 0 -2.27 0 mirMAP -0.22 4.0E-5 NA
103 hsa-miR-7-1-3p BCL2 1.84 0 -2.27 0 mirMAP -0.21 0.00021 NA
104 hsa-miR-7-5p BCL2 3.57 0 -2.27 0 miRNAWalker2 validate; miRTarBase; mirMAP -0.24 0 26464649; 25862909; 21750649 Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions
105 hsa-miR-96-5p BCL2 5.73 0 -2.27 0 miRNAWalker2 validate; TargetScan -0.26 0 NA
106 hsa-let-7a-5p BCL2L1 0.1 0.43289 0.65 0 TargetScan; miRNATAP -0.2 1.0E-5 26915294; 20347499 As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA
107 hsa-let-7b-5p BCL2L1 -0.07 0.65185 0.65 0 miRNATAP -0.12 0.00057 26915294; 20347499 As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA
108 hsa-let-7g-5p BCL2L1 1.16 0 0.65 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.07 0.03609 20347499 Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines; Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA
109 hsa-miR-140-5p BCL2L1 -0.89 0 0.65 0 PITA; miRanda; miRNATAP -0.1 0.00286 NA
110 hsa-miR-664a-5p BCL2L1 0.23 0.25436 0.65 0 mirMAP -0.08 0.0042 NA
111 hsa-miR-16-2-3p BIRC3 2.34 0 -0.22 0.47948 mirMAP -0.13 0.04984 NA
112 hsa-miR-374b-5p BIRC3 -0.16 0.22606 -0.22 0.47948 mirMAP -0.22 0.04644 NA
113 hsa-miR-651-5p BIRC3 1.64 0 -0.22 0.47948 MirTarget -0.17 0.00447 NA
114 hsa-miR-98-5p BIRC3 1.06 0 -0.22 0.47948 miRNAWalker2 validate -0.28 0.00772 NA
115 hsa-miR-107 CAPN2 1.81 0 -0.79 0 miRanda -0.19 0 NA
116 hsa-miR-16-2-3p CAPN2 2.34 0 -0.79 0 mirMAP -0.18 0 NA
117 hsa-miR-20a-3p CAPN2 1.64 0 -0.79 0 MirTarget -0.15 0 NA
118 hsa-miR-30a-5p CAPN2 0.2 0.42032 -0.79 0 miRNAWalker2 validate -0.08 0.00167 NA
119 hsa-miR-320a CAPN2 0.5 0.00226 -0.79 0 miRanda -0.11 0.0029 NA
120 hsa-miR-320b CAPN2 1.1 0 -0.79 0 miRanda -0.12 2.0E-5 NA
121 hsa-miR-320c CAPN2 0.73 0.00058 -0.79 0 miRanda -0.12 3.0E-5 NA
122 hsa-miR-421 CAPN2 2.1 0 -0.79 0 miRanda -0.17 0 NA
123 hsa-miR-590-3p CAPN2 1.73 0 -0.79 0 miRanda -0.11 0.00028 NA
124 hsa-miR-590-5p CAPN2 1.46 0 -0.79 0 miRanda -0.1 0.00306 NA
125 hsa-miR-7-5p CAPN2 3.57 0 -0.79 0 miRNAWalker2 validate -0.11 0 NA
126 hsa-miR-16-2-3p CASP10 2.34 0 -0.72 0.00202 mirMAP -0.14 0.00675 NA
127 hsa-miR-181c-5p CASP10 0.6 0.01077 -0.72 0.00202 mirMAP -0.11 0.02227 NA
128 hsa-miR-186-5p CASP10 1.01 0 -0.72 0.00202 MirTarget; mirMAP -0.23 0.00505 NA
129 hsa-miR-195-3p CASP10 -1.78 0 -0.72 0.00202 mirMAP -0.12 0.0036 NA
130 hsa-miR-19a-3p CASP10 1.85 0 -0.72 0.00202 MirTarget; mirMAP -0.14 0.0111 NA
131 hsa-miR-19b-3p CASP10 1.34 0 -0.72 0.00202 MirTarget; mirMAP -0.22 0.00084 NA
132 hsa-miR-200b-3p CASP10 4.57 0 -0.72 0.00202 mirMAP -0.12 0.00031 NA
133 hsa-miR-200c-3p CASP10 4.2 0 -0.72 0.00202 mirMAP -0.09 0.00801 NA
134 hsa-miR-30b-3p CASP10 0.97 0 -0.72 0.00202 MirTarget -0.2 0.00064 NA
135 hsa-miR-320a CASP10 0.5 0.00226 -0.72 0.00202 miRanda -0.21 0.0015 NA
136 hsa-miR-320b CASP10 1.1 0 -0.72 0.00202 miRanda -0.18 0.00058 NA
137 hsa-miR-320c CASP10 0.73 0.00058 -0.72 0.00202 miRanda -0.15 0.00479 NA
138 hsa-miR-33a-3p CASP10 1.39 0 -0.72 0.00202 mirMAP -0.27 0 NA
139 hsa-miR-3614-5p CASP10 3.22 0 -0.72 0.00202 mirMAP -0.06 0.04578 NA
140 hsa-miR-429 CASP10 5.04 0 -0.72 0.00202 mirMAP; miRNATAP -0.09 0.0024 NA
141 hsa-miR-532-5p CASP10 0.31 0.06801 -0.72 0.00202 mirMAP -0.22 0.00094 NA
142 hsa-miR-589-3p CASP10 1.7 0 -0.72 0.00202 mirMAP -0.2 1.0E-5 NA
143 hsa-miR-616-5p CASP10 1.97 0 -0.72 0.00202 mirMAP -0.11 0.01291 NA
144 hsa-miR-744-3p CASP10 2.12 0 -0.72 0.00202 mirMAP -0.29 0 NA
145 hsa-miR-766-3p CASP10 2.7 0 -0.72 0.00202 mirMAP -0.1 0.04345 NA
146 hsa-let-7c-5p CASP3 -1.72 0 0.88 0 MirTarget -0.11 0 NA
147 hsa-miR-101-3p CASP3 -1.48 0 0.88 0 MirTarget -0.2 0 NA
148 hsa-miR-139-5p CASP3 -2.41 0 0.88 0 miRanda -0.13 0 NA
149 hsa-miR-140-5p CASP3 -0.89 0 0.88 0 miRanda -0.13 2.0E-5 NA
150 hsa-miR-195-3p CASP3 -1.78 0 0.88 0 MirTarget -0.11 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 POSITIVE REGULATION OF RESPONSE TO STIMULUS 50 1929 6.578e-35 3.061e-31
2 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 22 99 1.609e-34 3.743e-31
3 CELL DEATH 40 1001 1.274e-33 1.976e-30
4 APOPTOTIC SIGNALING PATHWAY 28 289 2.112e-33 2.456e-30
5 INTRACELLULAR SIGNAL TRANSDUCTION 45 1572 2.552e-32 2.375e-29
6 REGULATION OF CELL DEATH 44 1472 3.153e-32 2.445e-29
7 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 46 1848 1.555e-30 1.034e-27
8 POSITIVE REGULATION OF CELL COMMUNICATION 43 1532 3.363e-30 1.889e-27
9 EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 16 39 3.653e-30 1.889e-27
10 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 42 1492 2.133e-29 9.927e-27
11 POSITIVE REGULATION OF MOLECULAR FUNCTION 44 1791 1.256e-28 5.312e-26
12 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 34 876 1.545e-27 5.992e-25
13 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 18 95 7e-27 2.505e-24
14 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 22 213 1.043e-26 3.372e-24
15 POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 21 179 1.087e-26 3.372e-24
16 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 41 1656 2.238e-26 6.507e-24
17 NEGATIVE REGULATION OF CELL DEATH 33 872 2.713e-26 7.424e-24
18 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 11 13 3.882e-26 1.003e-23
19 RESPONSE TO OXYGEN CONTAINING COMPOUND 38 1381 9.575e-26 2.345e-23
20 ZYMOGEN ACTIVATION 18 112 1.711e-25 3.982e-23
21 POSITIVE REGULATION OF CATALYTIC ACTIVITY 39 1518 1.948e-25 4.316e-23
22 RESPONSE TO CYTOKINE 30 714 5.04e-25 1.066e-22
23 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 17 98 1.052e-24 2.127e-22
24 IMMUNE SYSTEM PROCESS 42 1984 1.821e-24 3.53e-22
25 POSITIVE REGULATION OF CELL DEATH 28 605 2.132e-24 3.969e-22
26 REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING 21 233 3.243e-24 5.804e-22
27 POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 11 17 6.092e-24 1.05e-21
28 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 18 153 6.336e-23 1.053e-20
29 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 18 154 7.157e-23 1.148e-20
30 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 11 22 3.425e-22 5.312e-20
31 REGULATION OF APOPTOTIC SIGNALING PATHWAY 22 363 1.454e-21 2.183e-19
32 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 32 1135 1.636e-21 2.378e-19
33 REGULATION OF PHOSPHORUS METABOLIC PROCESS 36 1618 4.52e-21 6.373e-19
34 REGULATION OF PEPTIDASE ACTIVITY 22 392 7.731e-21 1.058e-18
35 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 18 200 8.99e-21 1.195e-18
36 CELLULAR RESPONSE TO CYTOKINE STIMULUS 25 606 1.804e-20 2.332e-18
37 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 30 1036 2.223e-20 2.653e-18
38 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 30 1036 2.223e-20 2.653e-18
39 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 17 171 2.154e-20 2.653e-18
40 REGULATION OF TRANSFERASE ACTIVITY 29 946 2.506e-20 2.915e-18
41 REGULATION OF KINASE ACTIVITY 27 776 2.963e-20 3.362e-18
42 PROTEIN MATURATION 19 265 5.14e-20 5.694e-18
43 REGULATION OF IMMUNE SYSTEM PROCESS 33 1403 7.964e-20 8.618e-18
44 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 11 34 1.344e-19 1.421e-17
45 CYTOKINE MEDIATED SIGNALING PATHWAY 22 452 1.667e-19 1.723e-17
46 REGULATION OF PROTEIN MODIFICATION PROCESS 35 1710 3.125e-19 3.161e-17
47 REGULATION OF IMMUNE RESPONSE 27 858 3.892e-19 3.853e-17
48 RESPONSE TO NITROGEN COMPOUND 27 859 4.01e-19 3.887e-17
49 POSITIVE REGULATION OF KINASE ACTIVITY 22 482 6.59e-19 6.258e-17
50 REGULATION OF PROTEOLYSIS 25 711 8.314e-19 7.737e-17
51 POSITIVE REGULATION OF PROTEOLYSIS 20 363 8.667e-19 7.907e-17
52 POSITIVE REGULATION OF IMMUNE RESPONSE 23 563 1.051e-18 9.409e-17
53 PHOSPHORYLATION 30 1228 2.609e-18 2.29e-16
54 ACTIVATION OF PROTEIN KINASE ACTIVITY 18 279 3.699e-18 3.187e-16
55 RESPONSE TO TUMOR NECROSIS FACTOR 17 233 4.419e-18 3.739e-16
56 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 21 470 7.369e-18 6.123e-16
57 I KAPPAB KINASE NF KAPPAB SIGNALING 12 70 1.364e-17 1.113e-15
58 ACTIVATION OF IMMUNE RESPONSE 20 427 2.064e-17 1.656e-15
59 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 18 321 4.47e-17 3.525e-15
60 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 11 55 5.304e-17 4.113e-15
61 PROTEIN PHOSPHORYLATION 26 944 5.503e-17 4.198e-15
62 POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS 25 867 8.948e-17 6.611e-15
63 REGULATION OF RESPONSE TO CYTOKINE STIMULUS 14 144 8.951e-17 6.611e-15
64 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 22 616 1.173e-16 8.528e-15
65 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 24 799 1.741e-16 1.246e-14
66 TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY 13 118 2.322e-16 1.637e-14
67 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 34 1977 2.778e-16 1.929e-14
68 CELLULAR RESPONSE TO NITROGEN COMPOUND 20 505 5.233e-16 3.581e-14
69 POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY 13 132 1.035e-15 6.982e-14
70 REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY 10 50 1.507e-15 1.002e-13
71 RESPONSE TO BIOTIC STIMULUS 24 886 1.755e-15 1.15e-13
72 POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 15 228 2.336e-15 1.51e-13
73 NEURON APOPTOTIC PROCESS 9 35 3.472e-15 2.213e-13
74 RESPONSE TO ABIOTIC STIMULUS 25 1024 4.213e-15 2.649e-13
75 INTRINSIC APOPTOTIC SIGNALING PATHWAY 13 152 6.668e-15 4.137e-13
76 POSITIVE REGULATION OF DEFENSE RESPONSE 17 364 7.708e-15 4.719e-13
77 TOLL LIKE RECEPTOR SIGNALING PATHWAY 11 85 8.706e-15 5.261e-13
78 INFLAMMATORY RESPONSE 18 454 1.885e-14 1.124e-12
79 CELLULAR RESPONSE TO ABIOTIC STIMULUS 15 263 1.933e-14 1.138e-12
80 REGULATION OF HYDROLASE ACTIVITY 27 1327 2.053e-14 1.194e-12
81 RESPONSE TO ENDOGENOUS STIMULUS 28 1450 2.086e-14 1.199e-12
82 REGULATION OF RESPONSE TO STRESS 28 1468 2.841e-14 1.612e-12
83 POSITIVE REGULATION OF HYDROLASE ACTIVITY 23 905 3.055e-14 1.713e-12
84 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 9 46 5.253e-14 2.91e-12
85 NEURON DEATH 9 47 6.479e-14 3.547e-12
86 RESPONSE TO EXTERNAL STIMULUS 30 1821 1.123e-13 6.077e-12
87 PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY 11 109 1.465e-13 7.837e-12
88 IMMUNE RESPONSE 24 1100 2.026e-13 1.071e-11
89 SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND 8 33 2.172e-13 1.123e-11
90 EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 8 33 2.172e-13 1.123e-11
91 CELLULAR RESPONSE TO MECHANICAL STIMULUS 10 80 2.223e-13 1.137e-11
92 REGULATION OF NEURON DEATH 14 252 2.251e-13 1.138e-11
93 RESPONSE TO BACTERIUM 18 528 2.479e-13 1.24e-11
94 ACTIVATION OF INNATE IMMUNE RESPONSE 13 204 3.045e-13 1.507e-11
95 IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 15 323 3.881e-13 1.901e-11
96 CELLULAR RESPONSE TO STRESS 27 1565 1.07e-12 5.188e-11
97 PROTEOLYSIS 24 1208 1.517e-12 7.279e-11
98 HOMEOSTATIC PROCESS 25 1337 1.71e-12 8.036e-11
99 POSITIVE REGULATION OF GENE EXPRESSION 28 1733 1.702e-12 8.036e-11
100 RESPONSE TO LIPID 21 888 2.074e-12 9.65e-11
101 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 15 365 2.257e-12 1.04e-10
102 FC EPSILON RECEPTOR SIGNALING PATHWAY 11 142 2.779e-12 1.268e-10
103 REGULATION OF NECROTIC CELL DEATH 7 26 3.269e-12 1.477e-10
104 POSITIVE REGULATION OF INNATE IMMUNE RESPONSE 13 246 3.315e-12 1.483e-10
105 NECROTIC CELL DEATH 7 28 5.852e-12 2.593e-10
106 PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS 8 49 6.745e-12 2.961e-10
107 T CELL APOPTOTIC PROCESS 6 15 7.87e-12 3.422e-10
108 CELLULAR RESPONSE TO EXTERNAL STIMULUS 13 264 8.084e-12 3.483e-10
109 RESPONSE TO WOUNDING 17 563 8.728e-12 3.726e-10
110 MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY 7 30 1e-11 4.232e-10
111 REGULATION OF DEFENSE RESPONSE 19 759 1.097e-11 4.598e-10
112 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 7 32 1.645e-11 6.773e-10
113 NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND 7 32 1.645e-11 6.773e-10
114 EXECUTION PHASE OF APOPTOSIS 8 55 1.791e-11 7.309e-10
115 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 24 1360 1.861e-11 7.528e-10
116 REGULATION OF CELL PROLIFERATION 25 1496 1.997e-11 8.009e-10
117 RESPONSE TO HORMONE 20 893 2.091e-11 8.315e-10
118 REGULATION OF INNATE IMMUNE RESPONSE 14 357 2.483e-11 9.789e-10
119 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 13 289 2.514e-11 9.83e-10
120 T CELL HOMEOSTASIS 7 34 2.614e-11 1.014e-09
121 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 14 360 2.775e-11 1.067e-09
122 LYMPHOCYTE APOPTOTIC PROCESS 6 18 2.895e-11 1.104e-09
123 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 14 370 3.991e-11 1.51e-09
124 NEGATIVE REGULATION OF CELL COMMUNICATION 22 1192 7.015e-11 2.632e-09
125 WOUND HEALING 15 470 8.081e-11 2.984e-09
126 NEGATIVE REGULATION OF MOLECULAR FUNCTION 21 1079 8.039e-11 2.984e-09
127 REGULATION OF MAP KINASE ACTIVITY 13 319 8.587e-11 3.146e-09
128 ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY 11 195 8.772e-11 3.189e-09
129 STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 9 103 1.02e-10 3.68e-09
130 CHEMICAL HOMEOSTASIS 19 874 1.229e-10 4.399e-09
131 RESPONSE TO PEPTIDE 14 404 1.273e-10 4.523e-09
132 DEFENSE RESPONSE 22 1231 1.301e-10 4.587e-09
133 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 8 71 1.496e-10 5.234e-09
134 LEUKOCYTE APOPTOTIC PROCESS 6 23 1.552e-10 5.39e-09
135 FC RECEPTOR SIGNALING PATHWAY 11 206 1.581e-10 5.448e-09
136 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 20 1008 1.806e-10 6.18e-09
137 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 26 1805 1.852e-10 6.291e-09
138 REGULATION OF EXECUTION PHASE OF APOPTOSIS 6 24 2.064e-10 6.959e-09
139 CELLULAR RESPONSE TO PEPTIDE 12 274 2.146e-10 7.183e-09
140 PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 6 25 2.708e-10 9.001e-09
141 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 15 514 2.804e-10 9.253e-09
142 PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS 9 120 4.053e-10 1.328e-08
143 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 9 121 4.367e-10 1.421e-08
144 LYMPHOCYTE HOMEOSTASIS 7 50 4.641e-10 1.5e-08
145 POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 7 51 5.364e-10 1.71e-08
146 NIK NF KAPPAB SIGNALING 8 83 5.363e-10 1.71e-08
147 INOSITOL LIPID MEDIATED SIGNALING 9 124 5.439e-10 1.722e-08
148 NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY 6 28 5.713e-10 1.796e-08
149 INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY 5 13 6.15e-10 1.92e-08
150 REGULATION OF CELLULAR PROTEIN LOCALIZATION 15 552 7.489e-10 2.323e-08
151 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 9 129 7.746e-10 2.387e-08
152 POSITIVE REGULATION OF MAPK CASCADE 14 470 9.152e-10 2.802e-08
153 REGULATION OF MAPK CASCADE 16 660 9.779e-10 2.974e-08
154 CELL ACTIVATION 15 568 1.107e-09 3.346e-08
155 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 19 1004 1.258e-09 3.778e-08
156 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS 6 32 1.359e-09 4.053e-08
157 REGULATION OF NEURON APOPTOTIC PROCESS 10 192 1.461e-09 4.329e-08
158 LEUKOCYTE CELL CELL ADHESION 11 255 1.521e-09 4.48e-08
159 CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY 6 33 1.656e-09 4.847e-08
160 LEUKOCYTE HOMEOSTASIS 7 60 1.745e-09 5.074e-08
161 T CELL RECEPTOR SIGNALING PATHWAY 9 146 2.328e-09 6.728e-08
162 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 6 36 2.889e-09 8.296e-08
163 ACTIVATION OF PROTEIN KINASE A ACTIVITY 5 17 2.925e-09 8.348e-08
164 POSITIVE REGULATION OF MAP KINASE ACTIVITY 10 207 3.025e-09 8.582e-08
165 POSITIVE REGULATION OF PROTEIN IMPORT 8 104 3.301e-09 9.31e-08
166 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 17 829 3.379e-09 9.472e-08
167 RESPONSE TO MECHANICAL STIMULUS 10 210 3.475e-09 9.682e-08
168 RESPONSE TO OXIDATIVE STRESS 12 352 3.695e-09 1.023e-07
169 POSITIVE REGULATION OF NEURON DEATH 7 67 3.853e-09 1.061e-07
170 REGULATION OF CATABOLIC PROCESS 16 731 4.227e-09 1.157e-07
171 REGULATION OF LIPID METABOLIC PROCESS 11 282 4.362e-09 1.187e-07
172 REGULATION OF MEMBRANE PERMEABILITY 7 70 5.266e-09 1.425e-07
173 LEUKOCYTE DIFFERENTIATION 11 292 6.268e-09 1.686e-07
174 CELLULAR RESPONSE TO HORMONE STIMULUS 14 552 7.169e-09 1.917e-07
175 CELLULAR GLUCOSE HOMEOSTASIS 7 75 8.598e-09 2.286e-07
176 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 6 43 8.866e-09 2.331e-07
177 CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS 6 43 8.866e-09 2.331e-07
178 NECROPTOTIC PROCESS 5 21 9.512e-09 2.486e-07
179 RESPONSE TO INORGANIC SUBSTANCE 13 479 1.19e-08 3.092e-07
180 RESPONSE TO OXYGEN LEVELS 11 311 1.204e-08 3.094e-07
181 HEMOSTASIS 11 311 1.204e-08 3.094e-07
182 RESPONSE TO TOXIC SUBSTANCE 10 241 1.299e-08 3.321e-07
183 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 6 47 1.544e-08 3.926e-07
184 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 12 404 1.715e-08 4.313e-07
185 REGULATION OF ORGANELLE ORGANIZATION 19 1178 1.715e-08 4.313e-07
186 POSITIVE REGULATION OF TRANSPORT 17 936 2.044e-08 5.114e-07
187 RESPONSE TO GAMMA RADIATION 6 50 2.266e-08 5.639e-07
188 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 10 258 2.481e-08 6.14e-07
189 REGULATION OF PROTEIN LOCALIZATION 17 950 2.541e-08 6.255e-07
190 CELLULAR RESPONSE TO INTERLEUKIN 1 7 88 2.651e-08 6.493e-07
191 PHOSPHATIDYLINOSITOL METABOLIC PROCESS 9 193 2.677e-08 6.521e-07
192 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 18 1087 2.981e-08 7.224e-07
193 REGULATION OF INTRACELLULAR TRANSPORT 14 621 3.15e-08 7.593e-07
194 LYMPHOCYTE ACTIVATION 11 342 3.193e-08 7.657e-07
195 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 6 53 3.247e-08 7.748e-07
196 MITOCHONDRIAL MEMBRANE ORGANIZATION 7 92 3.618e-08 8.589e-07
197 REGULATION OF CELL ADHESION 14 629 3.694e-08 8.724e-07
198 MULTICELLULAR ORGANISMAL HOMEOSTASIS 10 272 4.084e-08 9.597e-07
199 NEGATIVE REGULATION OF CATABOLIC PROCESS 9 203 4.14e-08 9.68e-07
200 REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 7 95 4.525e-08 1.053e-06
201 REGULATION OF NECROPTOTIC PROCESS 4 11 4.722e-08 1.088e-06
202 POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 4 11 4.722e-08 1.088e-06
203 PEPTIDYL SERINE MODIFICATION 8 148 5.335e-08 1.223e-06
204 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 5 29 5.43e-08 1.227e-06
205 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 5 29 5.43e-08 1.227e-06
206 POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING 5 29 5.43e-08 1.227e-06
207 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 10 282 5.733e-08 1.289e-06
208 GLYCEROLIPID BIOSYNTHETIC PROCESS 9 211 5.772e-08 1.291e-06
209 LIPID PHOSPHORYLATION 7 99 6.029e-08 1.342e-06
210 REGULATION OF GLUCOSE TRANSPORT 7 100 6.464e-08 1.432e-06
211 REGULATION OF GLUCOSE IMPORT 6 60 6.944e-08 1.526e-06
212 SINGLE ORGANISM CELL ADHESION 12 459 6.951e-08 1.526e-06
213 REGULATION OF ENDOTHELIAL CELL DEVELOPMENT 4 12 7.063e-08 1.529e-06
214 REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER 4 12 7.063e-08 1.529e-06
215 POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 12 7.063e-08 1.529e-06
216 RENAL SYSTEM PROCESS 7 102 7.416e-08 1.598e-06
217 REGULATION OF MITOCHONDRION ORGANIZATION 9 218 7.635e-08 1.63e-06
218 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 9 218 7.635e-08 1.63e-06
219 LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY 5 31 7.727e-08 1.642e-06
220 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 9 220 8.256e-08 1.746e-06
221 RESPONSE TO ORGANIC CYCLIC COMPOUND 16 917 9.999e-08 2.105e-06
222 CELLULAR RESPONSE TO BIOTIC STIMULUS 8 163 1.127e-07 2.363e-06
223 IMMUNE SYSTEM DEVELOPMENT 13 582 1.162e-07 2.424e-06
224 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 22 1784 1.21e-07 2.514e-06
225 REGULATION OF CELL ACTIVATION 12 484 1.235e-07 2.554e-06
226 PROTEIN KINASE B SIGNALING 5 34 1.255e-07 2.572e-06
227 RENAL WATER HOMEOSTASIS 5 34 1.255e-07 2.572e-06
228 RESPONSE TO ENDOPLASMIC RETICULUM STRESS 9 233 1.347e-07 2.749e-06
229 RESPONSE TO AMINO ACID 7 112 1.415e-07 2.874e-06
230 REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY 4 14 1.421e-07 2.874e-06
231 PHOSPHOLIPID BIOSYNTHETIC PROCESS 9 235 1.449e-07 2.918e-06
232 REGULATION OF TRANSPORT 22 1804 1.472e-07 2.952e-06
233 GLUCOSE HOMEOSTASIS 8 170 1.559e-07 3.099e-06
234 CARBOHYDRATE HOMEOSTASIS 8 170 1.559e-07 3.099e-06
235 NEGATIVE REGULATION OF NEURON DEATH 8 171 1.631e-07 3.229e-06
236 RESPONSE TO INTERLEUKIN 1 7 115 1.696e-07 3.345e-06
237 RESPONSE TO ACID CHEMICAL 10 319 1.807e-07 3.549e-06
238 LEUKOCYTE ACTIVATION 11 414 2.199e-07 4.3e-06
239 CELLULAR RESPONSE TO GLUCAGON STIMULUS 5 38 2.239e-07 4.359e-06
240 CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS 6 74 2.471e-07 4.791e-06
241 REGULATION OF PROTEIN IMPORT 8 183 2.743e-07 5.295e-06
242 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 7 126 3.17e-07 6.095e-06
243 RESPONSE TO DRUG 11 431 3.283e-07 6.287e-06
244 LEUKOCYTE MIGRATION 9 259 3.297e-07 6.287e-06
245 REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 4 17 3.351e-07 6.29e-06
246 ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY 4 17 3.351e-07 6.29e-06
247 REGULATION OF CELLULAR LOCALIZATION 18 1277 3.352e-07 6.29e-06
248 REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 4 17 3.351e-07 6.29e-06
249 PROTEIN OLIGOMERIZATION 11 434 3.517e-07 6.572e-06
250 REGULATION OF NIK NF KAPPAB SIGNALING 5 42 3.753e-07 6.957e-06
251 POSITIVE REGULATION OF GLUCOSE TRANSPORT 5 42 3.753e-07 6.957e-06
252 RESPONSE TO REACTIVE OXYGEN SPECIES 8 191 3.801e-07 7.019e-06
253 AGING 9 264 3.872e-07 7.121e-06
254 INSULIN RECEPTOR SIGNALING PATHWAY 6 80 3.942e-07 7.221e-06
255 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 17 1152 4.037e-07 7.366e-06
256 JNK CASCADE 6 82 4.568e-07 8.302e-06
257 REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 5 44 4.765e-07 8.627e-06
258 RESPONSE TO ALKALOID 7 137 5.599e-07 1.006e-05
259 ACTIVATION OF MAPK ACTIVITY 7 137 5.599e-07 1.006e-05
260 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 6 86 6.065e-07 1.085e-05
261 CELLULAR HOMEOSTASIS 13 676 6.401e-07 1.141e-05
262 NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 6 88 6.952e-07 1.235e-05
263 CELLULAR CHEMICAL HOMEOSTASIS 12 570 7.074e-07 1.252e-05
264 RESPONSE TO GLUCAGON 5 48 7.431e-07 1.31e-05
265 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 12 573 7.477e-07 1.313e-05
266 LYMPHOCYTE DIFFERENTIATION 8 209 7.525e-07 1.316e-05
267 RESPONSE TO IONIZING RADIATION 7 145 8.217e-07 1.432e-05
268 NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS 4 21 8.336e-07 1.447e-05
269 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 20 1672 8.773e-07 1.517e-05
270 REGULATION OF CELL CELL ADHESION 10 380 8.972e-07 1.546e-05
271 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 10 381 9.188e-07 1.578e-05
272 REGULATION OF CYTOPLASMIC TRANSPORT 11 481 9.682e-07 1.656e-05
273 GLYCEROPHOSPHOLIPID METABOLIC PROCESS 9 297 1.035e-06 1.763e-05
274 MITOCHONDRION ORGANIZATION 12 594 1.091e-06 1.853e-05
275 REGULATION OF LIPID CATABOLIC PROCESS 5 52 1.116e-06 1.887e-05
276 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 7 152 1.128e-06 1.902e-05
277 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 18 1395 1.216e-06 2.042e-05
278 POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 4 23 1.227e-06 2.053e-05
279 REGULATION OF HOMOTYPIC CELL CELL ADHESION 9 307 1.361e-06 2.261e-05
280 REGULATION OF PROTEIN TARGETING 9 307 1.361e-06 2.261e-05
281 CELL CELL ADHESION 12 608 1.391e-06 2.304e-05
282 REGULATION OF BODY FLUID LEVELS 11 506 1.586e-06 2.617e-05
283 PROTEIN COMPLEX BIOGENESIS 16 1132 1.672e-06 2.739e-05
284 PROTEIN COMPLEX ASSEMBLY 16 1132 1.672e-06 2.739e-05
285 RESPONSE TO RADIATION 10 413 1.899e-06 3.101e-05
286 MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS 5 58 1.935e-06 3.147e-05
287 DEVELOPMENTAL PROGRAMMED CELL DEATH 4 26 2.055e-06 3.331e-05
288 REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 5 59 2.108e-06 3.406e-05
289 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 7 167 2.118e-06 3.41e-05
290 RESPONSE TO CARBOHYDRATE 7 168 2.204e-06 3.536e-05
291 POSITIVE REGULATION OF CELL CELL ADHESION 8 243 2.328e-06 3.723e-05
292 REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION 4 27 2.406e-06 3.82e-05
293 DNA CATABOLIC PROCESS 4 27 2.406e-06 3.82e-05
294 RESPONSE TO VIRUS 8 247 2.628e-06 4.16e-05
295 RESPONSE TO METAL ION 9 333 2.654e-06 4.186e-05
296 NEGATIVE REGULATION OF KINASE ACTIVITY 8 250 2.874e-06 4.519e-05
297 HOMEOSTASIS OF NUMBER OF CELLS 7 175 2.89e-06 4.528e-05
298 RESPONSE TO CORTICOSTEROID 7 176 3.002e-06 4.673e-05
299 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 11 541 3.023e-06 4.673e-05
300 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 11 541 3.023e-06 4.673e-05
301 PROTEIN HETEROOLIGOMERIZATION 6 113 3.023e-06 4.673e-05
302 MITOCHONDRIAL TRANSPORT 7 177 3.116e-06 4.801e-05
303 REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 6 118 3.888e-06 5.971e-05
304 CELL PROLIFERATION 12 672 3.912e-06 5.988e-05
305 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 9 351 4.075e-06 6.217e-05
306 REGULATION OF CYTOKINE PRODUCTION 11 563 4.425e-06 6.729e-05
307 GLYCEROLIPID METABOLIC PROCESS 9 356 4.57e-06 6.927e-05
308 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 12 684 4.687e-06 7.081e-05
309 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 6 122 4.717e-06 7.103e-05
310 MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY 4 32 4.863e-06 7.3e-05
311 WATER HOMEOSTASIS 5 70 4.944e-06 7.397e-05
312 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 10 465 5.442e-06 8.116e-05
313 PHOSPHOLIPID METABOLIC PROCESS 9 364 5.47e-06 8.132e-05
314 RESPONSE TO UV 6 126 5.683e-06 8.422e-05
315 POSITIVE REGULATION OF CYTOKINE PRODUCTION 9 370 6.242e-06 9.22e-05
316 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 9 372 6.519e-06 9.599e-05
317 B CELL ACTIVATION 6 132 7.43e-06 0.000109
318 CELL DEVELOPMENT 17 1426 7.448e-06 0.000109
319 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 12 720 7.887e-06 0.000115
320 IMMUNE EFFECTOR PROCESS 10 486 8.014e-06 0.0001165
321 REGULATION OF VITAMIN METABOLIC PROCESS 3 12 9.218e-06 0.0001336
322 REGULATION OF INFLAMMATORY RESPONSE 8 294 9.452e-06 0.0001366
323 LIPID MODIFICATION 7 210 9.583e-06 0.0001373
324 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 6 138 9.589e-06 0.0001373
325 NEGATIVE REGULATION OF LIPID METABOLIC PROCESS 5 80 9.554e-06 0.0001373
326 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 11 616 1.035e-05 0.0001478
327 NEGATIVE REGULATION OF HYDROLASE ACTIVITY 9 397 1.098e-05 0.0001562
328 PLATELET ACTIVATION 6 142 1.129e-05 0.0001602
329 CELLULAR RESPONSE TO OXYGEN LEVELS 6 143 1.175e-05 0.0001662
330 HEPATOCYTE APOPTOTIC PROCESS 3 13 1.195e-05 0.0001675
331 RESPONSE TO COBALT ION 3 13 1.195e-05 0.0001675
332 POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION 3 13 1.195e-05 0.0001675
333 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 4 40 1.21e-05 0.000169
334 CELLULAR RESPONSE TO INSULIN STIMULUS 6 146 1.323e-05 0.0001843
335 REGULATION OF CELL DIFFERENTIATION 17 1492 1.351e-05 0.0001876
336 POSITIVE REGULATION OF CELL ACTIVATION 8 311 1.42e-05 0.0001967
337 RESPONSE TO TEMPERATURE STIMULUS 6 148 1.43e-05 0.0001974
338 TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY 3 14 1.517e-05 0.0002089
339 POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 5 88 1.523e-05 0.0002091
340 RESPONSE TO HEAT 5 89 1.609e-05 0.0002202
341 CELLULAR LIPID METABOLIC PROCESS 13 913 1.705e-05 0.0002327
342 NEGATIVE REGULATION OF PHOSPHORYLATION 9 422 1.783e-05 0.0002426
343 REGULATION OF LEUKOCYTE DIFFERENTIATION 7 232 1.827e-05 0.0002471
344 PROTEIN COMPLEX SUBUNIT ORGANIZATION 17 1527 1.826e-05 0.0002471
345 APOPTOTIC DNA FRAGMENTATION 3 15 1.892e-05 0.0002552
346 NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS 6 156 1.928e-05 0.0002593
347 POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION 4 45 1.946e-05 0.000261
348 REGULATION OF JNK CASCADE 6 159 2.147e-05 0.0002871
349 RESPONSE TO ANTIBIOTIC 4 47 2.317e-05 0.000309
350 MACROMOLECULAR COMPLEX ASSEMBLY 16 1398 2.426e-05 0.0003225
351 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS 4 48 2.521e-05 0.0003333
352 REGULATION OF LIPID KINASE ACTIVITY 4 48 2.521e-05 0.0003333
353 REGULATION OF DNA METABOLIC PROCESS 8 340 2.692e-05 0.0003549
354 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 13 957 2.794e-05 0.0003673
355 NEGATIVE REGULATION OF ANOIKIS 3 17 2.813e-05 0.0003687
356 REGULATION OF AUTOPHAGY 7 249 2.876e-05 0.0003759
357 INTRACELLULAR RECEPTOR SIGNALING PATHWAY 6 168 2.929e-05 0.0003818
358 ORGANOPHOSPHATE BIOSYNTHETIC PROCESS 9 450 2.954e-05 0.0003839
359 POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 4 50 2.968e-05 0.0003847
360 REGULATION OF CELLULAR RESPONSE TO STRESS 11 691 3e-05 0.0003878
361 CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM 7 252 3.105e-05 0.0004002
362 RESPONSE TO NICOTINE 4 51 3.212e-05 0.0004129
363 NEGATIVE REGULATION OF ORGANIC ACID TRANSPORT 3 18 3.367e-05 0.0004304
364 INOSITOL PHOSPHATE MEDIATED SIGNALING 3 18 3.367e-05 0.0004304
365 STRIATED MUSCLE CELL DIFFERENTIATION 6 173 3.454e-05 0.00044
366 REGULATION OF T CELL MEDIATED IMMUNITY 4 52 3.471e-05 0.00044
367 POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 4 52 3.471e-05 0.00044
368 CELLULAR RESPONSE TO ACID CHEMICAL 6 175 3.683e-05 0.0004657
369 REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS 4 53 3.744e-05 0.0004703
370 INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 5 106 3.75e-05 0.0004703
371 CELLULAR RESPONSE TO AMINO ACID STIMULUS 4 53 3.744e-05 0.0004703
372 DNA CATABOLIC PROCESS ENDONUCLEOLYTIC 3 19 3.988e-05 0.0004988
373 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 4 54 4.032e-05 0.000503
374 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 14 1142 4.084e-05 0.000508
375 REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 5 108 4.102e-05 0.000509
376 RESPONSE TO GROWTH FACTOR 9 475 4.498e-05 0.0005566
377 RESPONSE TO KETONE 6 182 4.586e-05 0.000566
378 POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 3 20 4.68e-05 0.0005746
379 REGULATION OF MACROPHAGE DIFFERENTIATION 3 20 4.68e-05 0.0005746
380 REGULATION OF MYELOID CELL DIFFERENTIATION 6 183 4.728e-05 0.000579
381 APOPTOTIC MITOCHONDRIAL CHANGES 4 57 4.997e-05 0.0006102
382 REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY 5 114 5.315e-05 0.0006473
383 B CELL HOMEOSTASIS 3 21 5.446e-05 0.0006599
384 RESPONSE TO NITRIC OXIDE 3 21 5.446e-05 0.0006599
385 POSITIVE REGULATION OF CELL ADHESION 8 376 5.487e-05 0.0006631
386 MYELOID CELL DIFFERENTIATION 6 189 5.658e-05 0.0006821
387 PROTEIN DEPHOSPHORYLATION 6 190 5.827e-05 0.0007005
388 BIOLOGICAL ADHESION 13 1032 6.086e-05 0.0007298
389 REGULATION OF MONOOXYGENASE ACTIVITY 4 60 6.119e-05 0.0007319
390 PROTEIN AUTOPHOSPHORYLATION 6 192 6.175e-05 0.0007367
391 REGULATION OF PROTEIN HOMODIMERIZATION ACTIVITY 3 22 6.29e-05 0.0007447
392 POSITIVE REGULATION OF PROTEIN OLIGOMERIZATION 3 22 6.29e-05 0.0007447
393 RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 22 6.29e-05 0.0007447
394 INNATE IMMUNE RESPONSE 10 619 6.324e-05 0.0007468
395 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY 9 498 6.476e-05 0.0007628
396 REGULATION OF PHOSPHOLIPID METABOLIC PROCESS 4 61 6.531e-05 0.0007654
397 REGULATION OF INTERLEUKIN 8 PRODUCTION 4 61 6.531e-05 0.0007654
398 EMBRYO DEVELOPMENT 12 894 6.639e-05 0.0007762
399 MEMBRANE ORGANIZATION 12 899 7.003e-05 0.0008166
400 REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 6 197 7.12e-05 0.0008282
401 POSITIVE REGULATION OF JUN KINASE ACTIVITY 4 63 7.415e-05 0.0008604
402 REGULATION OF ADAPTIVE IMMUNE RESPONSE 5 123 7.632e-05 0.0008811
403 T CELL DIFFERENTIATION 5 123 7.632e-05 0.0008811
404 REGULATION OF ANOIKIS 3 24 8.225e-05 0.0009473
405 REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS 4 65 8.383e-05 0.0009631
406 RESPONSE TO INSULIN 6 205 8.869e-05 0.001016
407 POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS 4 66 8.9e-05 0.001017
408 REGULATION OF LEUKOCYTE PROLIFERATION 6 206 9.109e-05 0.001039
409 REGULATION OF LIPID BIOSYNTHETIC PROCESS 5 128 9.217e-05 0.001043
410 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 5 128 9.217e-05 0.001043
411 POSITIVE REGULATION OF LIPID METABOLIC PROCESS 5 128 9.217e-05 0.001043
412 CELLULAR EXTRAVASATION 3 25 9.323e-05 0.001048
413 APOPTOTIC NUCLEAR CHANGES 3 25 9.323e-05 0.001048
414 EPITHELIAL CELL APOPTOTIC PROCESS 3 25 9.323e-05 0.001048
415 CELLULAR RESPONSE TO DRUG 4 67 9.44e-05 0.001058
416 POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION 5 131 0.0001028 0.00115
417 NEGATIVE REGULATION OF LIPID TRANSPORT 3 26 0.0001051 0.001173
418 REGULATION OF RESPONSE TO WOUNDING 8 413 0.0001055 0.001174
419 POSITIVE REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY 4 69 0.0001059 0.001176
420 REGULATION OF CELL CYCLE 12 949 0.000117 0.001297
421 NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS 5 135 0.0001185 0.001297
422 POSITIVE REGULATION OF LOCOMOTION 8 420 0.0001184 0.001297
423 POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 5 135 0.0001185 0.001297
424 REGULATION OF FATTY ACID TRANSPORT 3 27 0.000118 0.001297
425 LIPID BIOSYNTHETIC PROCESS 9 539 0.0001183 0.001297
426 REGULATION OF HEMOPOIESIS 7 314 0.0001237 0.001352
427 CELLULAR RESPONSE TO RADIATION 5 137 0.000127 0.001384
428 POSITIVE REGULATION OF ADAPTIVE IMMUNE RESPONSE 4 73 0.0001319 0.001418
429 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 28 0.0001318 0.001418
430 RESPONSE TO COPPER ION 3 28 0.0001318 0.001418
431 POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE 3 28 0.0001318 0.001418
432 POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 28 0.0001318 0.001418
433 POSITIVE REGULATION OF CELL PROLIFERATION 11 814 0.0001304 0.001418
434 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 4 74 0.0001391 0.001491
435 POSITIVE REGULATION OF CELL DIFFERENTIATION 11 823 0.0001436 0.001536
436 MUSCLE ADAPTATION 3 29 0.0001466 0.001554
437 GRANULOCYTE MIGRATION 4 75 0.0001465 0.001554
438 POSITIVE REGULATION OF MONOOXYGENASE ACTIVITY 3 29 0.0001466 0.001554
439 NEGATIVE REGULATION OF CELL CYCLE 8 433 0.000146 0.001554
440 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 10 689 0.0001528 0.001616
441 REGULATION OF CELL CYCLE PROCESS 9 558 0.0001535 0.001619
442 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 8 437 0.0001555 0.001637
443 NEGATIVE REGULATION OF B CELL ACTIVATION 3 30 0.0001625 0.0017
444 CELL MOTILITY 11 835 0.000163 0.0017
445 LOCALIZATION OF CELL 11 835 0.000163 0.0017
446 REGULATION OF ANION TRANSMEMBRANE TRANSPORT 3 30 0.0001625 0.0017
447 NEGATIVE REGULATION OF PROTEOLYSIS 7 329 0.000165 0.001718
448 REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 5 145 0.0001657 0.001721
449 LYMPHOCYTE COSTIMULATION 4 78 0.0001706 0.001768
450 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 5 147 0.0001766 0.001826
451 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 4 79 0.0001792 0.001847
452 POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION 3 31 0.0001794 0.001847
453 LIPID METABOLIC PROCESS 13 1158 0.0001931 0.001984
454 MUSCLE CELL DIFFERENTIATION 6 237 0.0001957 0.002006
455 POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION 4 81 0.0001974 0.002011
456 POSITIVE REGULATION OF T CELL MEDIATED IMMUNITY 3 32 0.0001975 0.002011
457 REGULATION OF JUN KINASE ACTIVITY 4 81 0.0001974 0.002011
458 ESTABLISHMENT OF LOCALIZATION IN CELL 16 1676 0.0002092 0.002125
459 CELLULAR RESPONSE TO LIPID 8 457 0.0002109 0.002138
460 NEGATIVE REGULATION OF ANION TRANSPORT 3 33 0.0002167 0.002192
461 REGULATION OF LEUKOCYTE MEDIATED IMMUNITY 5 156 0.0002329 0.00235
462 NEGATIVE REGULATION OF PEPTIDASE ACTIVITY 6 245 0.0002341 0.002357
463 CELLULAR RESPONSE TO ALKALOID 3 34 0.0002371 0.002382
464 POSITIVE REGULATION OF LEUKOCYTE MEDIATED IMMUNITY 4 85 0.0002377 0.002383
465 GAMETE GENERATION 9 595 0.0002475 0.002473
466 REGULATION OF MITOTIC CELL CYCLE 8 468 0.0002477 0.002473
467 REGULATION OF PROTEIN OLIGOMERIZATION 3 35 0.0002586 0.002577
468 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 9 602 0.0002698 0.002682
469 LEUKOCYTE PROLIFERATION 4 88 0.0002715 0.002694
470 T CELL PROLIFERATION 3 36 0.0002814 0.002786
471 B CELL DIFFERENTIATION 4 89 0.0002835 0.002795
472 EPITHELIAL CELL PROLIFERATION 4 89 0.0002835 0.002795
473 POSITIVE REGULATION OF HEMOPOIESIS 5 163 0.0002853 0.002806
474 REGULATION OF OXIDOREDUCTASE ACTIVITY 4 90 0.0002959 0.002899
475 RESPONSE TO ALCOHOL 7 362 0.0002955 0.002899
476 SINGLE ORGANISM CELLULAR LOCALIZATION 11 898 0.0003053 0.002985
477 REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS 4 94 0.0003494 0.003409
478 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 3 39 0.0003575 0.003465
479 ERBB2 SIGNALING PATHWAY 3 39 0.0003575 0.003465
480 SPLEEN DEVELOPMENT 3 39 0.0003575 0.003465
481 FC GAMMA RECEPTOR SIGNALING PATHWAY 4 95 0.0003638 0.003512
482 REGULATION OF LIPID TRANSPORT 4 95 0.0003638 0.003512
483 MULTICELLULAR ORGANISM REPRODUCTION 10 768 0.0003647 0.003513
484 RESPONSE TO STEROID HORMONE 8 497 0.0003706 0.003563
485 MYELOID LEUKOCYTE DIFFERENTIATION 4 96 0.0003786 0.003625
486 FEMALE GAMETE GENERATION 4 96 0.0003786 0.003625
487 REGULATION OF ACTIVATED T CELL PROLIFERATION 3 40 0.0003855 0.003683
488 MACROMOLECULE CATABOLIC PROCESS 11 926 0.0003964 0.003779
489 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 4 98 0.0004095 0.003897
490 MYELOID LEUKOCYTE MIGRATION 4 99 0.0004257 0.004041
491 SYSTEM PROCESS 16 1785 0.0004264 0.004041
492 CARDIOVASCULAR SYSTEM DEVELOPMENT 10 788 0.0004464 0.004213
493 CIRCULATORY SYSTEM DEVELOPMENT 10 788 0.0004464 0.004213
494 REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 4 101 0.0004592 0.004325
495 CELLULAR COMPONENT DISASSEMBLY 8 515 0.0004693 0.004411
496 MYELOID LEUKOCYTE MEDIATED IMMUNITY 3 43 0.0004778 0.004465
497 REGULATION OF POLYSACCHARIDE METABOLIC PROCESS 3 43 0.0004778 0.004465
498 RESPONSE TO LIGHT STIMULUS 6 280 0.0004769 0.004465
499 MUSCLE SYSTEM PROCESS 6 282 0.0004952 0.004617
500 CELLULAR RESPONSE TO OXIDATIVE STRESS 5 184 0.0004973 0.004628
501 GLAND DEVELOPMENT 7 395 0.0004986 0.004631
502 LOCOMOTION 12 1114 0.0005099 0.004727
503 DEPHOSPHORYLATION 6 286 0.0005333 0.004933
504 INTERSPECIES INTERACTION BETWEEN ORGANISMS 9 662 0.0005387 0.004963
505 SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 9 662 0.0005387 0.004963
506 THYMOCYTE AGGREGATION 3 45 0.0005467 0.005007
507 T CELL DIFFERENTIATION IN THYMUS 3 45 0.0005467 0.005007
508 REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS 3 45 0.0005467 0.005007
509 REGULATION OF CELL CYCLE ARREST 4 108 0.0005916 0.005408
510 RESPONSE TO HYDROGEN PEROXIDE 4 109 0.0006125 0.005588
511 POSITIVE REGULATION OF OXIDOREDUCTASE ACTIVITY 3 47 0.0006215 0.005659
512 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE 3 48 0.0006612 0.005998
513 REGULATION OF INTERLEUKIN 2 PRODUCTION 3 48 0.0006612 0.005998
514 REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS 2 11 0.0006694 0.006025
515 POSITIVE REGULATION OF HAIR CYCLE 2 11 0.0006694 0.006025
516 REGULATION OF FEVER GENERATION 2 11 0.0006694 0.006025
517 NEGATIVE REGULATION OF NECROTIC CELL DEATH 2 11 0.0006694 0.006025
518 OVULATION CYCLE 4 113 0.0007014 0.006287
519 REGULATION OF STEROID BIOSYNTHETIC PROCESS 3 49 0.0007026 0.006287
520 POSITIVE REGULATION OF INFLAMMATORY RESPONSE 4 113 0.0007014 0.006287
521 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 5 199 0.0007092 0.006334
522 PEPTIDYL AMINO ACID MODIFICATION 10 841 0.0007399 0.006595
523 REGULATION OF ORGANIC ACID TRANSPORT 3 50 0.0007455 0.006633
524 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 8 554 0.000757 0.006715
525 REGULATION OF IMMUNE EFFECTOR PROCESS 7 424 0.0007577 0.006715
526 FEMALE SEX DIFFERENTIATION 4 116 0.0007738 0.006845
527 PLASMA MEMBRANE ORGANIZATION 5 203 0.0007757 0.006849
528 TISSUE DEVELOPMENT 14 1518 0.0007878 0.006942
529 REGULATION OF CHEMOKINE BIOSYNTHETIC PROCESS 2 12 0.0008014 0.006983
530 I KAPPAB PHOSPHORYLATION 2 12 0.0008014 0.006983
531 REPLICATIVE SENESCENCE 2 12 0.0008014 0.006983
532 MYELIN MAINTENANCE 2 12 0.0008014 0.006983
533 POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS 2 12 0.0008014 0.006983
534 POSITIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS 2 12 0.0008014 0.006983
535 CELLULAR RESPONSE TO IONIZING RADIATION 3 52 0.0008364 0.007274
536 GLUCOSE METABOLIC PROCESS 4 119 0.0008513 0.00739
537 CYTOKINE PRODUCTION 4 120 0.0008783 0.007611
538 NEGATIVE REGULATION OF AUTOPHAGY 3 53 0.0008843 0.007634
539 GERM CELL DEVELOPMENT 5 209 0.000884 0.007634
540 REGULATION OF B CELL ACTIVATION 4 121 0.000906 0.007806
541 REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL 3 54 0.000934 0.008018
542 B CELL RECEPTOR SIGNALING PATHWAY 3 54 0.000934 0.008018
543 REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS 2 13 0.000945 0.008024
544 REGULATION OF MEMBRANE LIPID METABOLIC PROCESS 2 13 0.000945 0.008024
545 POSITIVE REGULATION OF STEROID BIOSYNTHETIC PROCESS 2 13 0.000945 0.008024
546 POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE 2 13 0.000945 0.008024
547 REGULATION OF HISTONE PHOSPHORYLATION 2 13 0.000945 0.008024
548 REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY 2 13 0.000945 0.008024
549 RESPONSE TO EXTRACELLULAR STIMULUS 7 441 0.0009532 0.008079
550 NEGATIVE REGULATION OF CELL CYCLE PROCESS 5 214 0.0009825 0.008312
551 REGULATION OF B CELL PROLIFERATION 3 55 0.0009853 0.008321
552 POSITIVE REGULATION OF HOMEOSTATIC PROCESS 5 216 0.001024 0.008633
553 REGULATION OF HOMEOSTATIC PROCESS 7 447 0.001031 0.008675
554 RESPONSE TO ESTROGEN 5 218 0.001067 0.008962
555 SEXUAL REPRODUCTION 9 730 0.001078 0.009036
556 ORGANOPHOSPHATE METABOLIC PROCESS 10 885 0.001091 0.009075
557 POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION 3 57 0.001093 0.009075
558 REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 57 0.001093 0.009075
559 REGULATION OF FIBROBLAST APOPTOTIC PROCESS 2 14 0.0011 0.009075
560 INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 14 0.0011 0.009075
561 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 2 14 0.0011 0.009075
562 T CELL MIGRATION 2 14 0.0011 0.009075
563 DETERMINATION OF ADULT LIFESPAN 2 14 0.0011 0.009075
564 NEGATIVE REGULATION OF ION TRANSPORT 4 127 0.001085 0.009075
565 NUCLEAR IMPORT 4 129 0.001149 0.009455
566 POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS 3 58 0.00115 0.009455
567 POSITIVE REGULATION OF CELL CYCLE 6 332 0.001157 0.009496
568 NEGATIVE REGULATION OF TRANSPORT 7 458 0.001187 0.009721
NumGOOverlapSizeP ValueAdj. P Value
1 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING 11 47 7.893e-18 7.332e-15
2 CYTOKINE RECEPTOR BINDING 16 271 1.362e-15 6.328e-13
3 KINASE ACTIVITY 23 842 6.616e-15 2.049e-12
4 DEATH RECEPTOR BINDING 7 18 1.618e-13 3.757e-11
5 ENZYME BINDING 29 1737 2.481e-13 3.841e-11
6 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 23 992 2.099e-13 3.841e-11
7 X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 8 43 2.206e-12 2.927e-10
8 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY 9 70 2.9e-12 2.993e-10
9 PROTEIN SERINE THREONINE KINASE ACTIVITY 16 445 2.881e-12 2.993e-10
10 CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS 6 15 7.87e-12 7.311e-10
11 PHOSPHATIDYLINOSITOL KINASE ACTIVITY 8 51 9.471e-12 7.745e-10
12 TUMOR NECROSIS FACTOR RECEPTOR BINDING 7 30 1e-11 7.745e-10
13 PROTEIN KINASE ACTIVITY 17 640 6.498e-11 4.643e-09
14 PROTEIN HETERODIMERIZATION ACTIVITY 15 468 7.613e-11 5.052e-09
15 PROTEASE BINDING 9 104 1.114e-10 6.898e-09
16 ADENYL NUCLEOTIDE BINDING 24 1514 1.72e-10 9.988e-09
17 DEATH RECEPTOR ACTIVITY 6 24 2.064e-10 1.128e-08
18 KINASE REGULATOR ACTIVITY 10 186 1.073e-09 5.537e-08
19 UBIQUITIN LIKE PROTEIN LIGASE BINDING 11 264 2.19e-09 1.071e-07
20 IDENTICAL PROTEIN BINDING 20 1209 4.24e-09 1.97e-07
21 RIBONUCLEOTIDE BINDING 24 1860 1.07e-08 4.734e-07
22 KINASE BINDING 14 606 2.321e-08 8.985e-07
23 CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 7 86 2.257e-08 8.985e-07
24 RECEPTOR BINDING 21 1476 2.24e-08 8.985e-07
25 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 5 30 6.498e-08 2.415e-06
26 PROTEIN DIMERIZATION ACTIVITY 18 1149 6.926e-08 2.475e-06
27 ENZYME REGULATOR ACTIVITY 16 959 1.84e-07 6.329e-06
28 PROTEIN KINASE A CATALYTIC SUBUNIT BINDING 4 15 1.932e-07 6.411e-06
29 PROTEIN PHOSPHATASE BINDING 7 120 2.271e-07 7.276e-06
30 INTERLEUKIN 1 RECEPTOR BINDING 4 16 2.569e-07 7.7e-06
31 PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY 4 16 2.569e-07 7.7e-06
32 MOLECULAR FUNCTION REGULATOR 18 1353 7.812e-07 2.268e-05
33 CAMP BINDING 4 23 1.227e-06 3.454e-05
34 PHOSPHATASE BINDING 7 162 1.729e-06 4.724e-05
35 PROTEIN DOMAIN SPECIFIC BINDING 12 624 1.823e-06 4.839e-05
36 CYSTEINE TYPE PEPTIDASE ACTIVITY 7 184 4.028e-06 0.0001039
37 SIGNAL TRANSDUCER ACTIVITY 19 1731 6.308e-06 0.0001584
38 INSULIN RECEPTOR SUBSTRATE BINDING 3 11 6.931e-06 0.0001694
39 CYCLIC NUCLEOTIDE BINDING 4 36 7.882e-06 0.0001877
40 PROTEIN KINASE A BINDING 4 42 1.474e-05 0.0003339
41 CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS 4 42 1.474e-05 0.0003339
42 KINASE INHIBITOR ACTIVITY 5 89 1.609e-05 0.000356
43 ENZYME INHIBITOR ACTIVITY 8 378 5.695e-05 0.00123
44 PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY 4 64 7.888e-05 0.001665
45 GROWTH FACTOR RECEPTOR BINDING 5 129 9.563e-05 0.001974
46 PROTEIN COMPLEX BINDING 12 935 0.0001017 0.002054
47 PROTEIN PHOSPHATASE 2A BINDING 3 28 0.0001318 0.002605
48 PROTEIN HOMODIMERIZATION ACTIVITY 10 722 0.000223 0.004315
49 HEAT SHOCK PROTEIN BINDING 4 89 0.0002835 0.005376
50 MACROMOLECULAR COMPLEX BINDING 14 1399 0.0003483 0.006471
51 PHOSPHOPROTEIN PHOSPHATASE ACTIVITY 5 178 0.0004275 0.007787
52 SCAFFOLD PROTEIN BINDING 3 45 0.0005467 0.009766
NumGOOverlapSizeP ValueAdj. P Value
1 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 17 237 5.902e-18 3.447e-15
2 CATALYTIC COMPLEX 27 1038 4.801e-17 1.402e-14
3 MEMBRANE MICRODOMAIN 17 288 1.581e-16 3.078e-14
4 PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX 8 20 2.044e-15 2.984e-13
5 MEMBRANE PROTEIN COMPLEX 23 1020 3.748e-13 4.378e-11
6 TRANSFERASE COMPLEX 18 703 2.939e-11 2.86e-09
7 PROTEIN KINASE COMPLEX 8 90 1.033e-09 8.621e-08
8 CILIARY BASE 5 23 1.564e-08 1.142e-06
9 PLASMA MEMBRANE PROTEIN COMPLEX 13 510 2.494e-08 1.618e-06
10 MEMBRANE REGION 18 1134 5.677e-08 3.316e-06
11 CYTOSOLIC PART 9 223 9.269e-08 4.921e-06
12 EXTRINSIC COMPONENT OF MEMBRANE 8 252 3.049e-06 0.0001484
13 CD40 RECEPTOR COMPLEX 3 11 6.931e-06 0.0002891
14 IKAPPAB KINASE COMPLEX 3 11 6.931e-06 0.0002891
15 RECEPTOR COMPLEX 8 327 2.038e-05 0.0007933
16 PHOSPHATASE COMPLEX 4 48 2.521e-05 0.0009202
17 MITOCHONDRION 16 1633 0.0001551 0.005327
18 INTRINSIC COMPONENT OF PLASMA MEMBRANE 16 1649 0.0001736 0.005631

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04210_Apoptosis 71 89 1.237e-185 2.189e-183
2 hsa04380_Osteoclast_differentiation 25 128 9.337e-38 8.264e-36
3 hsa04620_Toll.like_receptor_signaling_pathway 22 102 3.339e-34 1.97e-32
4 hsa04660_T_cell_receptor_signaling_pathway 22 108 1.34e-33 5.929e-32
5 hsa04662_B_cell_receptor_signaling_pathway 20 75 3.708e-33 1.313e-31
6 hsa04722_Neurotrophin_signaling_pathway 22 127 6.528e-32 1.926e-30
7 hsa04650_Natural_killer_cell_mediated_cytotoxicity 22 136 3.3e-31 8.344e-30
8 hsa04010_MAPK_signaling_pathway 26 268 6.085e-31 1.346e-29
9 hsa04370_VEGF_signaling_pathway 16 76 9.53e-25 1.874e-23
10 hsa04910_Insulin_signaling_pathway 18 138 9.127e-24 1.615e-22
11 hsa04062_Chemokine_signaling_pathway 17 189 1.222e-19 1.966e-18
12 hsa04973_Carbohydrate_digestion_and_absorption 11 44 3.504e-18 5.058e-17
13 hsa04914_Progesterone.mediated_oocyte_maturation 13 87 3.715e-18 5.058e-17
14 hsa04150_mTOR_signaling_pathway 11 52 2.7e-17 3.413e-16
15 hsa04664_Fc_epsilon_RI_signaling_pathway 12 79 6.406e-17 7.559e-16
16 hsa04510_Focal_adhesion 15 200 3.295e-16 3.645e-15
17 hsa04920_Adipocytokine_signaling_pathway 11 68 6.556e-16 6.826e-15
18 hsa04622_RIG.I.like_receptor_signaling_pathway 11 71 1.086e-15 1.068e-14
19 hsa04630_Jak.STAT_signaling_pathway 13 155 8.617e-15 8.028e-14
20 hsa04012_ErbB_signaling_pathway 11 87 1.136e-14 1.006e-13
21 hsa04666_Fc_gamma_R.mediated_phagocytosis 11 95 3.099e-14 2.612e-13
22 hsa04621_NOD.like_receptor_signaling_pathway 9 59 5.778e-13 4.648e-12
23 hsa04960_Aldosterone.regulated_sodium_reabsorption 8 42 1.8e-12 1.386e-11
24 hsa04115_p53_signaling_pathway 9 69 2.534e-12 1.869e-11
25 hsa04070_Phosphatidylinositol_signaling_system 8 78 3.233e-10 2.289e-09
26 hsa04720_Long.term_potentiation 7 70 5.266e-09 3.585e-08
27 hsa04670_Leukocyte_transendothelial_migration 8 117 8.427e-09 5.524e-08
28 hsa04623_Cytosolic_DNA.sensing_pathway 6 56 4.554e-08 2.879e-07
29 hsa04310_Wnt_signaling_pathway 8 151 6.236e-08 3.806e-07
30 hsa04114_Oocyte_meiosis 7 114 1.598e-07 9.426e-07
31 hsa04810_Regulation_of_actin_cytoskeleton 8 214 8.993e-07 5.135e-06
32 hsa04020_Calcium_signaling_pathway 7 177 3.116e-06 1.724e-05
33 hsa00562_Inositol_phosphate_metabolism 4 57 4.997e-05 0.000268
34 hsa04360_Axon_guidance 5 130 9.918e-05 0.0005163
35 hsa04640_Hematopoietic_cell_lineage 4 88 0.0002715 0.001373
36 hsa04141_Protein_processing_in_endoplasmic_reticulum 4 168 0.003014 0.01482
37 hsa04962_Vasopressin.regulated_water_reabsorption 2 44 0.01068 0.05107
38 hsa04530_Tight_junction 3 133 0.01183 0.05508
39 hsa04742_Taste_transduction 2 52 0.01469 0.06669
40 hsa04340_Hedgehog_signaling_pathway 2 56 0.01691 0.07484
41 hsa04976_Bile_secretion 2 71 0.02638 0.1139
42 hsa04971_Gastric_acid_secretion 2 74 0.02848 0.12
43 hsa04970_Salivary_secretion 2 89 0.03991 0.1638
44 hsa04540_Gap_junction 2 90 0.04073 0.1638
45 hsa04912_GnRH_signaling_pathway 2 101 0.0501 0.1928
46 hsa04916_Melanogenesis 2 101 0.0501 0.1928
47 hsa04270_Vascular_smooth_muscle_contraction 2 116 0.06399 0.241
48 hsa04110_Cell_cycle 2 128 0.07591 0.2799
49 hsa04120_Ubiquitin_mediated_proteolysis 2 139 0.08741 0.3158
50 hsa04740_Olfactory_transduction 2 388 0.4018 1

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

MAGI2-AS3

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-320c;hsa-miR-33a-3p;hsa-miR-421;hsa-miR-505-3p;hsa-miR-548v;hsa-miR-616-5p;hsa-miR-769-5p;hsa-miR-93-5p 17 AKT3 Sponge network -3.29 0.00119 -3.432 0 0.642
2

RP11-696N14.1

 hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-29a-3p;hsa-miR-338-5p;hsa-miR-584-5p 10 PIK3R1 Sponge network -0.342 0.704 -0.896 0.00072 0.469
3

HAND2-AS1

 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-146b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-320b;hsa-miR-421;hsa-miR-616-5p;hsa-miR-93-5p 13 AKT3 Sponge network -3.916 0.01209 -3.432 0 0.459
4

LINC00641

 hsa-let-7f-1-3p;hsa-let-7f-5p;hsa-let-7g-5p;hsa-let-7i-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-142-5p;hsa-miR-186-5p;hsa-miR-590-3p;hsa-miR-628-3p 10 PPP3CA Sponge network -1.526 0.02432 -0.565 4.0E-5 0.446
5

MAGI2-AS3

 hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-107;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-32-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-92a-3p 11 PRKAR2B Sponge network -3.29 0.00119 -2.601 0 0.439
6

MAGI2-AS3

 hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7d-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-194-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-32-3p;hsa-miR-339-5p;hsa-miR-429;hsa-miR-548v;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-7-1-3p;hsa-miR-93-5p 23 PRKACB Sponge network -3.29 0.00119 -1.289 0 0.42
7

HAND2-AS1

 hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-144-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-338-5p;hsa-miR-486-5p;hsa-miR-584-5p;hsa-miR-629-3p;hsa-miR-93-5p 19 PIK3R1 Sponge network -3.916 0.01209 -0.896 0.00072 0.374
8

EMX2OS

 hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-342-3p;hsa-miR-590-3p;hsa-miR-629-5p 12 BCL2 Sponge network -2.112 0.14094 -2.274 0 0.368
9 PLAC4 hsa-miR-103a-3p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-338-5p;hsa-miR-409-3p;hsa-miR-93-5p 11 PIK3R1 Sponge network 1.014 0.01175 -0.896 0.00072 0.347
10

RP1-60O19.1

 hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-205-5p;hsa-miR-20a-3p;hsa-miR-25-3p;hsa-miR-3200-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-320c;hsa-miR-33a-5p;hsa-miR-361-5p;hsa-miR-590-3p;hsa-miR-9-3p;hsa-miR-92a-3p 15 IRAK3 Sponge network -3.138 0.16483 -1.695 0 0.328
11

RP11-166D19.1

 hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-215-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-629-5p 20 BCL2 Sponge network -3.146 0.02178 -2.274 0 0.324
12

LINC00667

 hsa-let-7b-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-32-3p;hsa-miR-429;hsa-miR-548v;hsa-miR-96-5p 12 PRKACB Sponge network -2.558 0.01903 -1.289 0 0.31
13

USP3-AS1

 hsa-miR-103a-3p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-144-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-335-3p;hsa-miR-93-5p 14 PIK3R1 Sponge network -1.35 0.3108 -0.896 0.00072 0.303
14

RP11-166D19.1

 hsa-let-7d-3p;hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-194-3p;hsa-miR-200a-3p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-330-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-616-5p 12 PRKACB Sponge network -3.146 0.02178 -1.289 0 0.295
15

RP11-696N14.1

 hsa-miR-142-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-224-5p;hsa-miR-24-2-5p;hsa-miR-338-5p;hsa-miR-342-3p;hsa-miR-582-5p 11 BCL2 Sponge network -0.342 0.704 -2.274 0 0.291
16

RP11-161M6.2

 hsa-miR-107;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-769-5p;hsa-miR-93-5p 10 AKT3 Sponge network -0.737 0.61297 -3.432 0 0.278
17

CASC2

 hsa-miR-1301-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-486-5p;hsa-miR-629-3p 13 PIK3R1 Sponge network -2.463 0.00078 -0.896 0.00072 0.274
18

ZNF883

 hsa-let-7a-3p;hsa-let-7b-3p;hsa-let-7d-3p;hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-194-3p;hsa-miR-2110;hsa-miR-590-5p;hsa-miR-616-5p 11 PRKACB Sponge network -1.835 2.0E-5 -1.289 0 0.272
19

MAGI2-AS3

 hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-25-3p;hsa-miR-30e-5p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-320c;hsa-miR-429;hsa-miR-590-3p;hsa-miR-616-5p 17 PRKAR1A Sponge network -3.29 0.00119 -0.941 0 0.267
20

LINC00473

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-616-5p;hsa-miR-93-5p 14 AKT3 Sponge network -6.267 0.02511 -3.432 0 0.265
21

MAGI2-AS3

 hsa-miR-130b-5p;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-32-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-629-5p;hsa-miR-7-1-3p;hsa-miR-7-5p 24 BCL2 Sponge network -3.29 0.00119 -2.274 0 0.262
22

MAGI2-AS3

 hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-let-7g-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-3065-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-628-3p;hsa-miR-7-1-3p;hsa-miR-93-3p;hsa-miR-940 16 PPP3CA Sponge network -3.29 0.00119 -0.565 4.0E-5 0.26
23 LINC00663 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-33b-5p;hsa-miR-590-3p;hsa-miR-629-5p 10 BCL2 Sponge network -2.496 4.0E-5 -2.274 0 0.258

Quest ID: 79945d561880abe454b6c812f40531c6